Phio Pharmaceuticals Launches $6.36 Million At-The-Market Offering to Bolster Capital

summarizeSummary

Phio Pharmaceuticals Corp. has entered into an At-The-Market (ATM) offering agreement to sell up to $6.36 million of its common stock, providing additional capital but with potential for significant shareholder dilution.

check_boxKey Events · Financing and Capital Events · PHIO

• New At-The-Market Offering Launched

  Phio Pharmaceuticals Corp. entered into an At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of its common stock from time to time.

• Up to $6.36 Million in Potential Proceeds

  The company may offer and sell up to $6,360,000 of common stock under the ATM program, representing a substantial potential capital raise relative to its market capitalization.

• Sales Agent Commission

  H.C. Wainwright & Co., LLC will act as the sales agent and will receive a commission of 3.0% of the gross proceeds from each sale of shares.

• Use of Proceeds

  The net proceeds from the sale of shares will be used for general corporate purposes, as outlined in the prospectus.

auto_awesomeAnalysis · PHIO · Life Sciences

Phio Pharmaceuticals Corp. has initiated a substantial At-The-Market (ATM) offering, allowing it to sell up to $6.36 million in common stock. This represents a significant potential dilution for existing shareholders, given the company's current market capitalization. While ATM programs provide flexible access to capital, they typically create an overhang on the stock price. This move follows recent successful capital raises that addressed going concern doubts, indicating a continued need for funding to support operations and extend the company's financial runway. Investors should monitor the pace and pricing of sales under this program, as significant sales could exert downward pressure on the stock.